Metabolic Reprogramming in Neurofibromatosis Type 1: Plasma Metabolomic Signatures of MEK Inhibition Selumetinib reshapes systemic metabolism in NF1

Clicks: 19
ID: 327066
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #64 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Neurofibromatosis type 1 (NF1) is a tumor predisposition syndrome driven by RAS/MAPK hyperactivation due to neurofibromin loss. Although selumetinib has changed the management of inoperable plexiform neurofibromas (PNs), the systemic metabolic changes associated with NF1, PN burden, and MEK inhibition remain poorly understood. We aimed to identify circulating metabolomic signatures associated with NF1, tumor status, and selumetinib treatment. Methods We conducted a monocentric observational study at IRCCS Istituto Giannina Gaslini (Genoa, Italy). Seventy-five participants aged 3–30 years were enrolled in four age- and sex-matched groups: NF1 patients with inoperable PNs receiving selumetinib (≥4 cycles), NF1 patients with untreated PNs, NF1 patients without tumors, and healthy controls. Peripheral plasma samples were analyzed by high-resolution mass spectrometry–based metabolomics. Data processing was performed with MS-DIAL and MS-FINDER, followed by statistical analysis with Bonferroni correction. Pathway enrichment was assessed using KEGG and MetaboAnalyst 6.0. Results Distinct metabolomic profiles emerged across groups, with the largest differences observed in selumetinib-treated patients. Compared with untreated PN patients and healthy controls, treated patients showed downregulation of pathways related to central carbon metabolism and upregulation of amino acid–related pathways. Additional alterations involved lipid metabolism and mitochondrial-associated processes. NF1 patients without tumors showed fewer metabolic changes. Overall, PN status and MEK inhibition appeared to be the main drivers of systemic metabolic variation. Conclusions Selumetinib therapy in NF1 is associated with a distinct plasma metabolic signature, consistent with reduced proliferative energy metabolism and activation of adaptive amino acid and mitochondrial pathways. These findings support metabolomic profiling as a potential noninvasive tool for treatment monitoring and biomarker development in NF1-associated tumors.
Reference Key
openalex_W7204953587 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andrea Santangelo, Greta Volpedo, Adriana Blanda, Alessia Cafaro, Chiara Lavarello, Sebastiano Barco, Andrea Petretto, Gianluca Piccolo, Federico Zara, Giuliana Cangemi, Maria Cristina Diana, Pasquale Striano
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag224
URL
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdag224/70896176/vdag224.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.